Clinical trial
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
NCT00136539 · Harold J. Burstein, MD, PhD, Other · Completed
Key facts
| NCT number | NCT00136539 |
|---|---|
| Title | Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer |
| Official title | Neoadjuvant Therapy With Herceptin and Taxol for Stage II/III Breast Cancer |
| Lead sponsor | Harold J. Burstein, MD, PhD, Other |
| Collaborators | Dana-Farber Cancer Institute Genentech, Inc. Industry Bristol-Myers Squibb Massachusetts General Hospital Beth Israel Deaconess Medical Center Harvard Vanguard Medical Associates Brigham and Women's… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Herceptin, Taxol, Adriamycin, Cytoxan |
| Enrollment | 41 |
| Start date | Mar 1, 1999 |
| Primary completion | Nov 1, 2006 |
| Completion | Mar 1, 2012 |
| First posted | Aug 29, 2005 |
| Last update posted | Feb 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: